Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2
Top Cited Papers
Open Access
- 16 March 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cell Discovery
- Vol. 6 (1), 1-18
- https://doi.org/10.1038/s41421-020-0153-3
Abstract
Human coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV) and 2019 novel coronavirus (2019-nCoV, also known as SARS-CoV-2), lead global epidemics with high morbidity and mortality. However, there are currently no effective drugs targeting 2019-nCoV/SARS-CoV-2. Drug repurposing, representing as an effective drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV–host interactome and drug targets in the human protein–protein interaction network. Phylogenetic analyses of 15 HCoV whole genomes reveal that 2019-nCoV/SARS-CoV-2 shares the highest nucleotide sequence identity with SARS-CoV (79.7%). Specifically, the envelope and nucleocapsid proteins of 2019-nCoV/SARS-CoV-2 are two evolutionarily conserved regions, having the sequence identities of 96% and 89.6%, respectively, compared to SARS-CoV. Using network proximity analyses of drug targets and HCoV–host interactions in the human interactome, we prioritize 16 potential anti-HCoV repurposable drugs (e.g., melatonin, mercaptopurine, and sirolimus) that are further validated by enrichment analyses of drug-gene signatures and HCoV-induced transcriptomics data in human cell lines. We further identify three potential drug combinations (e.g., sirolimus plus dactinomycin, mercaptopurine plus melatonin, and toremifene plus emodin) captured by the “Complementary Exposure” pattern: the targets of the drugs both hit the HCoV–host subnetwork, but target separate neighborhoods in the human interactome network. In summary, this study offers powerful network-based methodologies for rapid identification of candidate repurposable drugs and potential drug combinations targeting 2019-nCoV/SARS-CoV-2.Keywords
Funding Information
- U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (K99HL138272, R00HL138272)
- U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute
This publication has 99 references indexed in Scilit:
- The Cellular Interactome of the Coronavirus Infectious Bronchitis Virus Nucleocapsid Protein and Functional Implications for Virus BiologyJournal of Virology, 2013
- Cell Host Response to Infection with Novel Human Coronavirus EMC Predicts Potential Antivirals and Important Differences with SARS CoronavirusmBio, 2013
- Transient Oligomerization of the SARS-CoV N Protein – Implication for Virus Ribonucleoprotein PackagingPLOS ONE, 2013
- Acute eosinophilic pneumonia related to a mesalazine suppositoryAsia Pacific Allergy, 2013
- Systematic identification of synergistic drug pairs targeting HIVNature Biotechnology, 2012
- Prediction of Drug-Target Interactions and Drug Repositioning via Network-Based InferencePLoS Computational Biology, 2012
- ChEMBL: a large-scale bioactivity database for drug discoveryNucleic Acids Research, 2011
- Discovery and Preclinical Validation of Drug Indications Using Compendia of Public Gene Expression DataScience Translational Medicine, 2011
- BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinitiesNucleic Acids Research, 2006
- UniProt: the Universal Protein knowledgebaseNucleic Acids Research, 2004